CIRIUM
23.11.2022 09:01:59 CET | Business Wire | Press release
Cirium has revealed today the aviation industry’s first satellite-based aircraft maintenance tracking feature in its Ascend Profiles module.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221123005132/en/
Cirium's new Ground Events feature shows how Air France redesigned the cabins of all 15 of its Airbus A330 fleet. (Photo: Business Wire)
Its new Ground Events feature enables aircraft and engine manufacturers, maintenance, repair and overhaul service providers, parts suppliers, lessors and insurers to monitor and predict future aircraft maintenance events.
This means businesses can better understand when and where an aircraft last had a maintenance event and forecast its next visit.
It also helps to identify aircraft transitions and define strategies around how and where maintenance and aftermarket budgets are being allocated by operators or owners.
Jeremy Bowen, CEO at Cirium said: “We are innovators and constantly looking to surface new ideas to empower the aviation industry.
“By tracking each Ground Event of an airline’s aircraft, we can identify whether it was for redesigned cabins, new aircraft branding, a maintenance event, or for its return to service.”
The first phase of the new Ground Events feature captures all instances when aircraft spend over seven days on the ground and identifies the aircraft registration, airport, arrival date and time, departure date and time, ground event duration (in days) and aircraft age. For specific airlines the feature showcases the types of maintenance activity and the provider.
The new feature demonstrates the power of combining Cirium’s unrivaled fleets and advanced satellite-based flight tracking data with the MRO locations and MRO relationships data.
In one example, it shows Air France has been redesigning the cabin interiors of all 15 of their Airbus A330 fleet to match the interiors of their A350 aircraft.
This reflects the carrier’s focus on enhancing the passenger experience and benefitted the airline when air travel started to return post the COVID-19 lockdowns. All 15 A330s were ready to return to service with the new interiors installed in July 2020.
Meanwhile, the feature shows how Lufthansa returned five of their Airbus A340s, which were due for retirement, back into service as the pandemic impacted the deliveries of new aircraft.
It further records how the airline partnered with IAC in Dublin to repaint the A340s in the new Lufthansa livery and regular maintenance checks were conducted by Lufthansa Technik Malta, Lufthansa Technik Philippines, and Joramco.
Given the increased demand during the pandemic for the shipment of PPE and the rise of ecommerce, Cirium’s Ground Events data shows how Federal Express (FedEx) were able to maximize their fleet and leverage strong relationships with their maintenance provider. FedEx ramped up their cargo flights, utilizing young aircraft – around one-to-eight years old – and maintained a consistent two-year maintenance cycle.
The Ground Events feature is part of the Ascend Profiles User Interface (UI) which visualizes aircraft intelligence of airline and lessor profiles and provides quick insights around aircraft types, airport locations, OEMs, MROs and more. The is available as an app and works across desktop, mobile and tablet. Find out more.
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221123005132/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
